BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Entasis Therapeutics

Entasis Therapeutics logo

Founded
2015
Patents
10
Clinical Trials
9
Publications
26

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

Become a Member to view additional information about this company

Posts Mentioning This Company